SCHEMBL6080184

SCHEMBL6080184

Cc1c(C(=O)O)nc2c([N+](=O)[O-])ccc(Br)c2c1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
TSHR P16473 4/20 0.38
CTSB P07858 1/20 0.37
CTSH P09668 1/20 0.37
TDP1 Q9NUW8 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CASP6 P55212 1/20 0.34
MAPT P10636 4/20 0.34
POLB P06746 2/20 0.34
KDM4E B2RXH2 2/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34
GPR35 Q9HC97 2/20 0.33
BLM P54132 2/20 0.33
GALK1 P51570 1/20 0.33
CDK2 P24941 1/20 0.33
EPRS1 P07814 1/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP2D6 P10635 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080809 0.81 EPRS1 (0.36) KMT2ATDP1MAPTKDM4EGPR35
SCHEMBL6080453 0.80 TSHR (0.40) MEN1KMT2ATSHRCTSBCTSH
SCHEMBL6079966 0.78 KMT2A (0.40) MEN1KMT2AMAPTALDH1A1
SCHEMBL6081119 0.76 RNASEH1 (0.44) MEN1KMT2ATSHRTDP1L3MBTL1
SCHEMBL6080679 0.76 TSHR (0.49) MEN1KMT2ATSHRCTSBTDP1
SCHEMBL6080247 0.74 ERN1 (0.40) MEN1KMT2ATSHRCTSBCTSH
SCHEMBL6591570 0.74 CASP6 (0.39) MEN1KMT2ATSHRCTSBCTSH
SCHEMBL6591568 0.74 CASP6 (0.39) MEN1KMT2ATSHRCTSBCTSH
SCHEMBL6080445 0.70 MAPT (0.47) TDP1L3MBTL1MAPTPOLBCYP1A2
SCHEMBL6079937 0.69 MAPT (0.41) MEN1KMT2ATDP1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL MEN1 740/4885KMT2A 1384/4885TSHR 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.